Analysis and occurrence of adverse events with oral anticoagulant therapy

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue 1, 1999, Pages 65-72

  Schenk, Joachim F ^a,c   Mörsdorf, Stefan ^a   Pindur, Gerhard ^a   Munter, Karl Heinz ^b   Thrun, Frank ^b   Tiaden, Jörg D ^b   Wenzel, Ernst ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Drug Comm of the Ger M Profession   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

'Saarland Model'; Adverse events; Bleeding; Oral anticoagulation; Phoenix database; Spontaneous report system

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; PHENPROCOUMON; WARFARIN;

ADOLESCENT; ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATHEROSCLEROSIS; BLEEDING; DATA BASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG SAFETY; GERMANY; HUMAN; HYPERTENSION; INCIDENCE; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK FACTOR;

EID: 0032908519     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996426     Document Type: Article

References (42)

1. 1. Hull RD. Anticoagulant treatment. Int Angiol 1995;14:32-43
2. 2. Levine MN, Raskob GE, Landefeld S, Hirsh J. Hemorrhagic complications of anticoagulant treatment. Chest 1995;108, Suppl:276-290
3. 3. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997;42:857-865
4. 4. Sarasin FP, Bounameaux H. Antithrombotic strategy after total hip replacement. A cost-effectiveness analysis comparing prolonged oral anticoagulants with screening for deep vein thrombosis. Arch Intern Med 1996;156:1661-1668
5. 5. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:227-228
6. 6. Katsuki T, Saito M, Noda T, Yaginuma T, Hosoda S. Long-term follow-up in patients receiving anticoagulation therapy: potency of therapy and complications. J Cardiol 1994;24: 203-209
7. 7. Meade TW. Thrombosis and cardiovascular disease. Ann Epidemiol 1992;2:353-364
8. 8. Haemostasis and Thrombosis Task Force for the British Committee for Standards in Haematology. Guideline. Guidelines on oral anticoagulation: Third edition. Br J Haematol 1998;101: 374-387
9. 9. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: A population based study in Rochester Minnesota. Mayo Clin Proc 1995;70:806-808
10. 10. Palareti G, Leali N, Coccheri S, et al. Hemorrhagic complications of oral anticoagulant therapy. Results of a prospective multicenter study ISCOAT (Italian Study on Complications of Oral Anticoagulant Therapy). G Ital Cardiol 1997;27:231-243
11. 11. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333:5-10
12. 12. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89:635-641
13. 13. Van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993;153:1557-1562
14. 14. Van der Meer FJ, Rosendaal FR, Vandenhroucke JP, Briet E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemostas 1996;76: 12-16
15. 15. Hull RD, Delmore T, Carter C, et al. Adjusted subcutaneous heparin vs. warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982;306:189-194
16. 16. Morocutti C, Amabile G, Fattaposta F, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale). Stroke 1997;28:1015-1021
17. 17. Coon WW, Willis PW. Recurrence of venous thromboembolism. Surgery 1973;73:823-827
18. 18. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long term treatment of venous thrombosis. N Engl J Med 1979;301:855-xxx
19. 19. Gurwitz JH, Goldberg RJ, Holden A, Knapic N, Ansell MA. Age-related risks of long term oral anticoagulant therapy. Arch Intern Med 1988;148:1733-1736
20. 20. Hull RD, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in thetreatment of proximal vein thrombosis. N Engl J Med 1982;307:1676-1681
21. 21. Smith RE. The INR: A perspective. Semin Thromb Hemostas 1997;23:547-549
22. 22. Ansell JE, Patel N, Ostrovski D, et al. Long-term patient self-management of oral anticoagulation. Arch Intern Med 1995; 155:2185-2189
23. 23. Ansell JE, Hamke AK, Holden A, Knapic N. Cost effectiveness of monitoring warfarin therapy using standard versus capillary prothrombin times. Am J Clin Pathol 1989;91:587-598
24. 24. Klein KL, Berdeaux DH, Milhollen JD, et al. Equal effectiveness of very-low-intensity anticoagulalion and standard low-intensity anticoagulation: A pilot study. South Med J 1995;88:1136-1139
25. 25. Fitzmaurice DA, Hobbs FD, Murray ET, Bradley CP, Holder R. Evaluation of computerized decision support for oral anticoagulalion management based in primary care. Br J Gen Pract 1996;46:533-535
26. 26. OASIS Investigators (Organization to Assess Strategies for Ischemic Syndromes). Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study. Circulation 1997;96:769-777
27. 27. Mörsdorf S, Leipnitz G, Pindur G, et al. Improved therapeutic safety in of oral anticoagulant therapy: The Saarland Model. Semin Thromb Hemostas 1999;25:49-56
28. 28. Schenk JF, Mörsdorf S, Munter KH, el al. Optimized therapy with oral anticoagulants. Risk benefit analysis. Danubean League Against Thrombosis and Hemorrhagic Disorders. 11th Meeting, Frankfurt/M-Germany 1998
29. 29. Munter KH, Schenk JF, Thrun F, et al. The Phoenix ADR Database of the Drug Commission of the German Medical Profession - Clinically useful approach to optimize evidence based medicine in Germany. Semin Thromb Hemostas 1999; 25:57-64
30. 30. GUSTO 2b Investigators. The global use of strategies to open occluded coronary arteries in acute coronary syndromes (GUSTO IIb) Angioplasly Substudy Investigators. A clinical trial comparing primary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336: 1621-1628
31. 31. Serruys PW, Herrman JP, Simon R, et al. A comparison of hirudin with heparin in the prevention of reslenosis after coronary angioplasty. HELVETICA Investigators. N Engl J Med 1995; 333:757-763
32. 32. Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction. (TIMI) 9B trial. Circulation 1996;94:911-921
33. 33. Bittl JA. Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. The Hirulog Angioplasty Study Investigators. Am Heart J 1995;130:658-665
34. 34. Adgey AA. Bleeding complications with new antithrombotics used in isehaemic heart disease. Haemostasis 1996;26:237-246
35. 35. Wheeldon M, Cumberland D. Pharmacological prevention of acute ischemic complications of coronary angioplasty. Cathet Cardiovasc Diagn 1997;42:249-256
36. 36. Cimminiello C, Uberti T, Fiorista F, Marzegalli M. Antiaggregating therapy in acute myocardial infarction. Eur Heart J 1991;12(Suppl. G):30-32
37. 37. Schellinger PD, Orberk E, Hacke W. Antithrombotic therapy after cerebral ischemia. Fortschr Neurol Psychiatr 1997;65: 425-434
38. 38. Wenzel E, Hellstern P. Hämostaseologische Diagnostik. Rationelle Differential-diagnose der Blutungs-und der Thromboseneigung in der Chirurgie. In: Häring R, Zilch H, eds. Diagnose und Differentialdiagnose in der Chirurgie und benachbarten Fachgebieten. Weinheim: Chapman & Hall; 1995:305-367
39. 39. Breddin H. Blutungen und Thrombosen. In Rahn KH, ed. Erkrankungen durch Arzneimittel. Stuttgart: Thieme Verlag; 1984:310-324
40. 40. Lämmle B, Hardegger T, Straub PW, Vock P, Furlan M. Internal bleeding in patients on oral anticoagulants. Schweiz Med Wochenschr 1993;123:701-710
41. 41. Sorano GG, Biondi G, Conti M, et al. Controlled vitamin K content diet for improving the management of poorly controlled anticoagulated patients: a clinical practice proposal. Haemostasis 1993;23:77-82
42. 42. Booth SL, Charnley JM, Sadowski JA, et al. Dietary vitamin K1 and stability or oral anticoagulation: proposal of a diet with constant vitamin K1 content. Thromb Haemostas 1997;77: 504-509